Compare Conagra Brands Inc (CAG) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Conagra Brands Inc vs GSK plc — how do they compare? Conagra Brands Inc trades at $14.95 (market cap $7.14B), while GSK plc trades at $50.33 (market cap $102.60B). The key difference: GSK plc is far larger — about 14.4× Conagra Brands Inc's market cap, and Conagra Brands Inc pays the higher dividend (8.2%). Which is the better fit depends on your goals.
| CAG | GSK | |
|---|---|---|
Market Cap | $7.14B | $102.60B |
Sector | Consumer Staples | Health |
52-Week High | $20.02 | $61.18 |
52-Week Low | $12.58 | $38.22 |
Enterprise Value | $14.20B | $123.04B |
Dividend Yield | 8.2% | 3.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Conagra Brands (CAG) trades at $15.06, up 1.89% with mixed technical signals showing neutral overall momentum. The company faces fundamental challenges with negative net income margin (-16.99%) and ROE (-25.06%) despite recent earnings beats. Recent developments include a 50% dividend cut to $0.18, new executive appointments, and strategic shifts under CEO John Brase to address margin pressure and declining sales.
While CAG's low valuation (P/E 10.06, P/S 0.63) offers potential upside, persistent revenue declines and margin compression present significant headwinds. Analyst consensus remains cautious with 62.5% hold ratings, though the company's debt reduction efforts and operational simplification could support a turnaround if execution improves.
GSK trades at $50.27, down 3.62% today, with a bearish technical signal but strong fundamentals including a P/E of 16.02 and net income margin of 14.52%. Recent quarters show earnings beats, and the company announced a $2.52 billion cost-saving plan to boost its drug pipeline. Cash flow from operations remains robust at $7.74 billion for 2025.
The outlook is mixed: analyst consensus leans hold (55.18%) amid valuation concerns, but revenue growth and pipeline investments support long-term potential. Key risks include competitive pressures and regulatory uncertainty, as highlighted by recent news on vaccine policies. The stock offers a dividend yield with payments scheduled through 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Conagra Brands Inc
Conagra Brands is a packaged food company that operates predominantly in the United States (over 90% of revenue and profits). It has a significant presence in the freezer aisle, with brands such as Marie Callender's, Healthy Choice, Banquet, and Birds Eye. Other popular brands include Duncan Hines, Hunt's, Slim Jim, Vlasic, Orville Redenbacher's, Reddi-wip, Wish-Bone, and Chef Boyardee. While the majority of revenue is sold into the U.S. retail channel, 9% of fiscal 2022 sales were to the food-service channel, down from 11% in fiscal 2019 due to the pandemic.
Read more on CAG →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
